Size：10
P1(RMB)：2430
MW：1323.52
One letter sequence：Pyr-HWSYh(Bzl)-LRP-NHEt
Molecular Formula：C66H86N18O12
Description：As a potent LHRH agonist, histrelin stimulates LH and FSH release and inhibits the actions of sex steroids on the male and female reproductive tracts. Its potency in vivo and in vitro is similar to that of the D-Trp6-containing analog. Especially because of its high water solubility and greater lipophilic character, histrelin appears promising for clinical application.Slow-release implants containing histreline implants were approved for the palliative treatment of advanced hormone-dependent prostate cancer.
Literature Reference：K.Sundaram et al., Life Sci., 28, 83 (1981)\nJ.DeFazio et al., Endocr. Res., 10, 163 (1984)\nM.J.Gibson and D.S.Kohtz, Contraception, 31, 91 (1985)\nM.J.Karten and J.E.Rivier, Endocr. Rev., 7, 44 (1986)\nG.C.Doelle et al., Horm. Metab. Res., 18, 201 (1986)\nJ.W.Gunnet et al., J. Endocrinol., 131, 211 (1991)\nM.Montagner et al., Reprod. Fertil. Dev., 17, 222 (2005)\nMerck Index, 14th ed., No. 4722, (2006)\nE.D.Deeks, Drugs, 70, 623 (2010)\nN.Shore et al., BJU Int., 109, 226 (2012)
Cas：220810-26-4